Ask AI
ProCE Banner Activity

My Thoughts on New and Exciting Advances with Immune Checkpoint Blockade for Treatment of Bladder Cancer

Clinical Thought
In this commentary, bladder cancer expert Matthew Galsky, MD, answers questions on the use of immune checkpoint blockade in first-line treatment, switch maintenance, and adjuvant therapy.

Released: November 19, 2020

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Bristol Myers Squibb

Pfizer and EMD Serono

Faculty Disclosure

Primary Author

Matthew Galsky, MD

Lillian and Howard Stratton Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director, Genitourinary Medical Oncology
Co-Leader, Cancer Clinical Investigation Program
Associate Director for Translational Research
Tisch Cancer Institute
New York, New York

Matthew Galsky, MD, has disclosed that he has received funds for research support from AstraZeneca, Bristol-Myers Squibb, Genentech, Merck, Pfizer, and Seattle Genetics and consulting fees from AstraZeneca, Bristol-Myers Squibb, Genentech, Jansen, Merck, Pfizer, and Seattle Genetics.